Will Celldex Therapeutics (CLDX) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 11/03/20
Celldex Therapeutics Initiates Phase 1b Study of CDX-0159 in Chronic Spontaneous UrticariaGlobeNewsWire • 10/13/20
Is the Options Market Predicting a Spike in Celldex Therapeutics (CLDX) Stock?Zacks Investment Research • 09/29/20
Celldex Therapeutics Initiates Phase 1 Study of New Bispecific Product Candidate CDX-527 in Solid TumorsGlobeNewsWire • 08/24/20
Celldex Therapeutics' (CLDX) CEO Anthony Marucci on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Celldex to Report Second Quarter 2020 Financial Results and Host Corporate Update CallGlobeNewsWire • 08/03/20
Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/29/20
Celldex Therapeutics, Inc. (CLDX) Shares March Higher, Can It Continue?Zacks Investment Research • 07/08/20
Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 06/18/20
Celldex Therapeutics Announces Pricing of $130.4 Million Public Offering of Common StockGlobeNewsWire • 06/16/20
Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock OptionsZacks Investment Research • 06/11/20
Celldex’s KIT Inhibitor CDX-0159 Demonstrates Profound, Sustained Dose-dependent Reductions in Plasma Tryptase—an Indicator of Mast Cell Burden—and a Favorable Safety ProfileGlobeNewsWire • 06/06/20